CA3180351A1 - Leriglitazone for treating lung inflammation and interstitial lung disease - Google Patents
Leriglitazone for treating lung inflammation and interstitial lung diseaseInfo
- Publication number
- CA3180351A1 CA3180351A1 CA3180351A CA3180351A CA3180351A1 CA 3180351 A1 CA3180351 A1 CA 3180351A1 CA 3180351 A CA3180351 A CA 3180351A CA 3180351 A CA3180351 A CA 3180351A CA 3180351 A1 CA3180351 A1 CA 3180351A1
- Authority
- CA
- Canada
- Prior art keywords
- phenyl
- ethoxy
- subject
- lung
- dione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382356 | 2020-04-30 | ||
| EP20382356.2 | 2020-04-30 | ||
| PCT/IB2021/053651 WO2021220250A1 (en) | 2020-04-30 | 2021-04-30 | Leriglitazone for treating lung inflammation and interstitial lung disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3180351A1 true CA3180351A1 (en) | 2021-11-04 |
Family
ID=70779625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3180351A Pending CA3180351A1 (en) | 2020-04-30 | 2021-04-30 | Leriglitazone for treating lung inflammation and interstitial lung disease |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230172921A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4142720A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023525981A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230035522A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116390725A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021265345A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022021951A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3180351A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL297771A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022013021A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021220250A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020013181A (es) | 2018-06-06 | 2021-02-26 | Minoryx Therapeutics S L | Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona. |
| JP2026500743A (ja) * | 2022-12-28 | 2026-01-08 | ミノリックス セラピューティクス エセ.エレ. | レリグリタゾンの最適投薬 |
| WO2024231881A2 (en) * | 2023-05-09 | 2024-11-14 | Minoryx Therapeutics S.L. | Polymorphic forms and formulations of leriglitazone |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2222272B1 (en) * | 2008-08-07 | 2012-11-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| WO2010150014A1 (en) * | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
| US20120190637A1 (en) * | 2009-10-14 | 2012-07-26 | Gemmus Pharma, Inc. | Combination therapy treatment for viral infections |
| WO2011073662A1 (en) * | 2009-12-17 | 2011-06-23 | Astrazeneca Ab | Combination of a benzoxazinone and a further agent for treating respiratory diseases |
| NZ725492A (en) | 2014-04-02 | 2023-06-30 | Minoryx Therapeutics S L | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
| MX379710B (es) * | 2016-12-01 | 2025-03-11 | Minoryx Therapeutics S L | 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]]-1,3-tiazolidin-2,4-diona para el tratamiento de enfermedad de higado graso no alcoholico. |
| MX2020013182A (es) * | 2018-06-06 | 2021-02-26 | Minoryx Therapeutics S L | Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales. |
-
2021
- 2021-04-30 CN CN202180043546.3A patent/CN116390725A/zh active Pending
- 2021-04-30 WO PCT/IB2021/053651 patent/WO2021220250A1/en not_active Ceased
- 2021-04-30 US US17/997,393 patent/US20230172921A1/en not_active Abandoned
- 2021-04-30 AU AU2021265345A patent/AU2021265345A1/en not_active Abandoned
- 2021-04-30 MX MX2022013021A patent/MX2022013021A/es unknown
- 2021-04-30 JP JP2022566063A patent/JP2023525981A/ja active Pending
- 2021-04-30 KR KR1020227042096A patent/KR20230035522A/ko not_active Abandoned
- 2021-04-30 BR BR112022021951A patent/BR112022021951A2/pt not_active IP Right Cessation
- 2021-04-30 IL IL297771A patent/IL297771A/en unknown
- 2021-04-30 CA CA3180351A patent/CA3180351A1/en active Pending
- 2021-04-30 EP EP21723015.0A patent/EP4142720A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP4142720A1 (en) | 2023-03-08 |
| CN116390725A (zh) | 2023-07-04 |
| US20230172921A1 (en) | 2023-06-08 |
| MX2022013021A (es) | 2023-01-16 |
| IL297771A (en) | 2022-12-01 |
| BR112022021951A2 (pt) | 2022-12-13 |
| AU2021265345A1 (en) | 2022-12-08 |
| JP2023525981A (ja) | 2023-06-20 |
| KR20230035522A (ko) | 2023-03-14 |
| WO2021220250A1 (en) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Magro | COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking | |
| US20230241014A1 (en) | Mek-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm | |
| US20230172921A1 (en) | Leriglitazone for treating lung inflammation and interstitial lung disease | |
| US20110295365A1 (en) | Anti-viral compositions and methods for administration | |
| US20230084300A1 (en) | Prevention and treatment of infections including those caused by coronavirus | |
| US20230218596A1 (en) | Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection | |
| US11052073B1 (en) | Sphingosine kinase 2 inhibitor for treating coronavirus infection | |
| US20230157994A1 (en) | New compositions and methods of treating covid-19 disease | |
| US20240082202A1 (en) | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | |
| Mahajan et al. | Plcγ2/Tmem178 dependent pathway in myeloid cells modulates the pathogenesis of cytokine storm syndrome | |
| US20230021647A1 (en) | Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l | |
| US20220288155A1 (en) | Cxcr4 inhibitor for the treatment of acute respiratory distress syndrome and viral infections | |
| Tutak et al. | A patient presenting with ARDS after COVID-19 vaccination: a COVID-19 case report | |
| US20180169108A1 (en) | Drug Combinations For the Treatment of HIV | |
| JP2023517220A (ja) | 微生物感染症の治療のためのnk細胞およびそれらの使用 | |
| CA3182210A1 (en) | Methods and compositions for treating coronavirus infectious disease | |
| JP2023512062A (ja) | 関節の炎症を治療するためにモメロチニブを使用する方法 | |
| HK40096631A (en) | Leriglitazone for treating lung inflammation and interstitial lung disease | |
| EP4115885A1 (en) | A pharmaceutical composition comprising bay 86-5277 and salts thereof for use in the treatment of viral infections and hyperinflammation | |
| TW202245799A (zh) | 治療冠狀病毒感染及由其導致之發炎所誘發的肺損傷之方法 | |
| US11471448B2 (en) | Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia | |
| RU2837859C1 (ru) | Лечение коронавирусной инфекции | |
| Haw et al. | TLR7 promotes smoke-induced lung damage through the activity of mast cell tryptase | |
| Arish et al. | Targeting a macrophage stemness factor to mitigate diseases post respiratory viral infection | |
| Ramezaninejad et al. | The Efficacy and Safety of Adding Chlorpromazine to Atazanavir/Ritonavir Regimen in the Treatment of Moderate COVID-19 Patients, a Randomized Double-blind Clinical Trial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251015 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251215 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260204 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE Effective date: 20260407 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260611 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260709 |